These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 19033564)

  • 21. [Cetuximab for patients with metastatic colorectal cancer-from the result of recent clinical trials].
    Ariyama H; Kusaba H; Baba E
    Gan To Kagaku Ryoho; 2010 May; 37(5):782-6. PubMed ID: 20495306
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cetuximab.
    Graham J; Muhsin M; Kirkpatrick P
    Nat Rev Drug Discov; 2004 Jul; 3(7):549-50. PubMed ID: 15272498
    [No Abstract]   [Full Text] [Related]  

  • 23. Clinical use of monoclonal antibodies to the epidermal growth factor receptor in colorectal cancer.
    Burtness B
    Oncology (Williston Park); 2007 Jul; 21(8):964-70; discussion 970, 974, 976-7. PubMed ID: 17715697
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Molecular biomarker development for anti-EGFR therapy: moving beyond EGFR expression.
    Chu E
    Clin Colorectal Cancer; 2008 May; 7(3):162. PubMed ID: 18621632
    [No Abstract]   [Full Text] [Related]  

  • 25. [Use of anti-EGFR antibodies (cetuximab and panitumumab) in the treatment of metastatic colorectal cancer in KRAS wild type patients].
    Smith D; Bosacki C; Merrouche Y
    Bull Cancer; 2009 Dec; 96 Suppl():S31-40. PubMed ID: 20034868
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab.
    Khambata-Ford S; Garrett CR; Meropol NJ; Basik M; Harbison CT; Wu S; Wong TW; Huang X; Takimoto CH; Godwin AK; Tan BR; Krishnamurthi SS; Burris HA; Poplin EA; Hidalgo M; Baselga J; Clark EA; Mauro DJ
    J Clin Oncol; 2007 Aug; 25(22):3230-7. PubMed ID: 17664471
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Should KRAS mutations be considered an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab?
    Garassino MC; Farina G; Rossi A; Martelli O; Torri V
    J Clin Oncol; 2008 May; 26(15):2600; author reply 2601-2. PubMed ID: 18487581
    [No Abstract]   [Full Text] [Related]  

  • 28. [Impact of mutational status of KRAS in the care of patients with colorectal cancer metastasis].
    Assenat E; Ychou M
    Bull Cancer; 2009 Dec; 96 Suppl():S41-6. PubMed ID: 20034869
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.
    Di Nicolantonio F; Martini M; Molinari F; Sartore-Bianchi A; Arena S; Saletti P; De Dosso S; Mazzucchelli L; Frattini M; Siena S; Bardelli A
    J Clin Oncol; 2008 Dec; 26(35):5705-12. PubMed ID: 19001320
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Some problems facing the molecular targeting therapy for colorectal cancer].
    Xu JM
    Zhonghua Zhong Liu Za Zhi; 2009 May; 31(5):321-3. PubMed ID: 19799077
    [No Abstract]   [Full Text] [Related]  

  • 31. K-ras mutations and cetuximab in colorectal cancer.
    De Roock W; Lambrechts D; Tejpar S
    N Engl J Med; 2009 Feb; 360(8):834; author reply 835-6. PubMed ID: 19238676
    [No Abstract]   [Full Text] [Related]  

  • 32. Anti-epidermal growth factor receptor antibodies in the treatment of metastatic colorectal cancer.
    Lee D
    Clin Colorectal Cancer; 2004 Sep; 4(3):159-62. PubMed ID: 15377399
    [No Abstract]   [Full Text] [Related]  

  • 33. Chemotherapy and immunotherapy in metastatic colorectal cancer.
    Loupakis F; Di Maio M; Falcone A
    N Engl J Med; 2009 May; 360(20):2135; author reply 2135-6. PubMed ID: 19445032
    [No Abstract]   [Full Text] [Related]  

  • 34. K-ras mutations and cetuximab in colorectal cancer.
    Codacci-Pisanelli G; Spinelli G; Tomao S
    N Engl J Med; 2009 Feb; 360(8):835; author reply 835-6. PubMed ID: 19238679
    [No Abstract]   [Full Text] [Related]  

  • 35. Prospective cost-effectiveness analysis of cetuximab in metastatic colorectal cancer: evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 trial.
    Mittmann N; Au HJ; Tu D; O'Callaghan CJ; Isogai PK; Karapetis CS; Zalcberg JR; Evans WK; Moore MJ; Siddiqui J; Findlay B; Colwell B; Simes J; Gibbs P; Links M; Tebbutt NC; Jonker DJ; ;
    J Natl Cancer Inst; 2009 Sep; 101(17):1182-92. PubMed ID: 19666851
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Effect of KRAS mutation on efficacy of Cetuximab combined with chemotherapy in advanced colorectal cancer patients].
    Pu XX; Deng YH; Xu F; Xiao J; Guo HQ; Huang H; Tian Y; He YJ; Lin TY
    Zhonghua Wei Chang Wai Ke Za Zhi; 2009 Nov; 12(6):594-7. PubMed ID: 19921572
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Epidermal growth factor receptor as a therapeutic target in colorectal cancer.
    Cohen RB
    Clin Colorectal Cancer; 2003 Feb; 2(4):246-51. PubMed ID: 12620146
    [TBL] [Abstract][Full Text] [Related]  

  • 38. First-line treatment of patients with metastatic colorectal cancer: an overview of recent data on chemotherapy plus targeted agents.
    Cercek A; Saltz LB
    Clin Colorectal Cancer; 2008 Dec; 7 Suppl 2():S47-51. PubMed ID: 19064406
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Anti-EGFR monoclonal antibodies in metastatic colorectal cancer: time for an individualized approach?
    Fakih M
    Expert Rev Anticancer Ther; 2008 Sep; 8(9):1471-80. PubMed ID: 18759698
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Genomics arrives to the clinical practices in colorectal cancer].
    Jankilevich G
    Acta Gastroenterol Latinoam; 2009 Mar; 39(1):81-4. PubMed ID: 19408743
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.